The U.S. Food and Drug Administration (FDA) has cleared women's imaging firm Hologic's Localizer radiofrequency identification (RFID) breast lesion localization device for long-term placement.
Localizer consists of an implantable tag that can be detected by a portable, handheld reader that indicates the location and distance to the lesion, the company said. The clearance allows the device to be implanted more than 30 days prior to breast-conserving surgery.
